CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a cash flow conversion efficiency ratio of 0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.33 Million) by net assets ($-30.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CERo Therapeutics Holdings, Inc. Common market cap and net worth for the company's overall valuation and market capitalisation.
CERo Therapeutics Holdings, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore earnings quality score of CERo Therapeutics Holdings, Inc. Common to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ProstaLund AB
ST:PLUN
|
-0.052x |
|
Strikewell Energy Corp
V:SKK
|
0.000x |
|
Tinybuild Inc
LSE:TBLD
|
0.161x |
|
Kollect on Demand Holding Ab
ST:KOLL
|
-0.012x |
|
Glen Eagle Resources Inc
V:GER
|
0.307x |
|
EUROPA MET. LTD POST CONS
F:WRE1
|
N/A |
|
Satis Group S.A.
WAR:STS
|
0.000x |
|
SolarWorld Aktiengesellschaft
HM:SWVK
|
N/A |
Annual Cash Flow Conversion Efficiency for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. View CERo Therapeutics Holdings, Inc. Common share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-5.45 Million | $-16.08 Million | 2.952x | -3.39% |
| 2024-12-31 | $-1.89 Million | $-5.79 Million | 3.056x | +2119.92% |
| 2023-12-31 | $-42.06 Million | $-5.79 Million | 0.138x | +131.12% |
| 2022-12-31 | $2.47 Million | $-1.09 Million | -0.442x | -10742.21% |
| 2021-12-31 | $170.83 Million | $-697.11K | -0.004x | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.